Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: J Thorac Oncol. 2011 Apr;6(4):661–670. doi: 10.1097/JTO.0b013e31820c9e3c

Figure 1.

Figure 1

Panel a. Ritonavir inhibits growth of the lung adenocarcinoma lines A549 and H522. Ritonavir inhibited the growth of both lines, exhibiting an IC50 of 35μM for A549 (open circles) and 42μM for H5222 (open squares). Results are representative of three consistent experiments.

Panel b. Ritonavir reduces the clonogenic efficiency of the lung adenocarcinoma lines A549 and H522. Ritonavir was efficient in reducing the clonogenic efficiency in both the A549 (open circles) and H522 (open squares) lines, exhibiting an IC50 of 30 and 40 μM, respectively.

Panel c. Ritonavir induces apoptosis in the lung adenocarcinoma lines A549 and H522. Ritonavir significantly increased early and late apoptotic events in both lines. The results are representative of two consistent experiments.